Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report
<p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old J...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-07-01
|
Series: | Journal of Medical Case Reports |
Online Access: | http://www.jmedicalcasereports.com/content/6/1/181 |
id |
doaj-c2f39d1b58bb4903aa66d05341311500 |
---|---|
record_format |
Article |
spelling |
doaj-c2f39d1b58bb4903aa66d053413115002020-11-25T01:05:31ZengBMCJournal of Medical Case Reports1752-19472012-07-016118110.1186/1752-1947-6-181Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case reportChokyu IsaoIshibashi KenichiGoto TakeoOhata Kenji<p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa epidural approach. His phosphate level recovered to a normal range immediately after the surgery.</p> <p>Conclusions</p> <p>It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced osteomalacia.</p> http://www.jmedicalcasereports.com/content/6/1/181 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chokyu Isao Ishibashi Kenichi Goto Takeo Ohata Kenji |
spellingShingle |
Chokyu Isao Ishibashi Kenichi Goto Takeo Ohata Kenji Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report Journal of Medical Case Reports |
author_facet |
Chokyu Isao Ishibashi Kenichi Goto Takeo Ohata Kenji |
author_sort |
Chokyu Isao |
title |
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
title_short |
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
title_full |
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
title_fullStr |
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
title_full_unstemmed |
Oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
title_sort |
oncogenic osteomalacia associated with mesenchymal tumor in the middle cranial fossa: a case report |
publisher |
BMC |
series |
Journal of Medical Case Reports |
issn |
1752-1947 |
publishDate |
2012-07-01 |
description |
<p>Abstract</p> <p>Introduction</p> <p>Tumor-induced osteomalacia is a paraneoplastic syndrome of hypophosphatemia. Osteomalacia causes multiple bone fractures and severe pain.</p> <p>Case presentation</p> <p>We report the case of a 57-year-old Japanese man with tumor-induced osteomalacia associated with a middle cranial fossa bone tumor. The tumor was successfully resected by using a middle fossa epidural approach. His phosphate level recovered to a normal range immediately after the surgery.</p> <p>Conclusions</p> <p>It is rare that tumor-induced osteomalacia originates from the middle skull base. This report suggests that, if patients have a clinical and biochemical picture suggestive of tumor-induced osteomalacia, it is crucial to perform a meticulous examination to detect the tumor or the lesion responsible for the tumor. The serum level of fibroblast growth factor 23 is the most reliable marker for evaluating the treatment outcome of tumor-induced osteomalacia.</p> |
url |
http://www.jmedicalcasereports.com/content/6/1/181 |
work_keys_str_mv |
AT chokyuisao oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport AT ishibashikenichi oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport AT gototakeo oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport AT ohatakenji oncogenicosteomalaciaassociatedwithmesenchymaltumorinthemiddlecranialfossaacasereport |
_version_ |
1725194138175930368 |